Rossari Biotech Limited — Important, 25-04-2025: Updates

The Board of Directors of Rossari Biotech Limited convened a meeting and approved key resolutions impacting its strategic and operational trajectory. They approved the audited financial results for the quarter and financial year ended March 31, 2025, reporting a substantial increase in revenue to ₹20,843.03 million from ₹18,380.04 million in the previous year, with a net profit after tax of ₹1,363.78 million.

The board declared a final dividend of ₹0.50 per share (25% of face value), which is subject to member approval at the upcoming Annual General Meeting. They also appointed M/s. Shah Patel & Associates as the Secretarial Auditor for a five-year term starting from FY 2025-2026.

Moreover, the Board sanctioned the grant of 834,250 stock options under the existing Employee Stock Option Plan, allowing for incentive alignment with employee performance. Notably, a capacity addition plan was approved, expected to increase production capacity by 13,000 MTPA with an estimated investment of ₹95 Crore, positioning the company to meet growing market demands. This strategic capacity expansion aligns with their goals for growth and market competitiveness. Investor sentiment may lean positively due to improved financial performance and growth initiatives.